Opinion
Video
Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer
Panelists discuss frontline maintenance therapies for advanced ovarian cancer, focusing on the impact of BRCA and HRD statuses on treatment selection and the choice between combination therapy (PARPi + bev) and monotherapy.
Video content above is prompted by the following:
- How do you typically approach biomarker testing for advanced ovarian cancer?
- When do you test and what type of testing do you perform?
- Which biomarkers do you generally access (e.g., BRCA1/2, HRD, etc) and how do results help guide your treatment approach?
- Briefly review frontline maintenance therapy options for advanced ovarian cancer and discuss key factors that drive your selection among available therapies.
- How do BRCA and HRD statuses influence your choice of maintenance therapy?
- When may you opt for a combination (PARPi + bev) vs monotherapy approach?
Related Videos
Related Content
